This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialtypharmacies continue to dominate the dispensing of specialty drugs. DCI has identified nearly 1,900 dispensing locations with specialtypharmacy accreditation.
Four critical components in which the right specialtypharmacy partner can bring rare and gene therapy manufacturers the scale, expertise and capabilities needed to drive enhanced patient access.
National Association of SpecialtyPharmacy (NASP) 2022 Annual Meeting & Expo. The National Association of SpecialtyPharmacy (NASP) will host the NASP 2022 Annual Meeting & Expo September 19-22. September 19-22, 2022 | Gaylord Palms Resort & Convention Center | Orlando, FL. www.naspnet.org/annualmeeting.
As many of you know, hospitals and health systems have emerged as significant participants in the specialtypharmacy industry. A new American Society of Hospital Pharmacists (ASHP) survey provides fresh insights into these specialtypharmacies. drug channels gets most of the attention. d/b/a Drug Channels Institute.
Hospitals and health systems are rapidly expanding their internal specialtypharmacies—and they’re using questionable tactics to boost revenues and profits. Nearly two-thirds of the larger health system specialtypharmacies operate as the exclusive pharmacy within self-insured health systems’ networks.
Informa Connect's Hub and SpecialtyPharmacy Models West. September 14-15, 2022 Sheraton San Diego Hotel & Marina | San Diego, CA www.informaconnect.com/hub-specialty-pharmacy-west. Delivered as a Hybrid Event. Drug Channels readers will save 10% off the current registration rate when they use code 22DC10 *.
It's time for Drug Channels annual update of vertical integration among insurers, PBMs, specialtypharmacies, and healthcare services within U.S. drug channels. As you can see below, we have revised, renovated, and refurbished our infamous illustration of the major vertical business relationships among the largest companies.
specialtypharmacies—via white, brown, and clear bagging—continue to displace buy-and-bill distribution channels for provider-administered oncology drugs. The battle for the specialty patient pits hospitals against insurers—and their respective specialtypharmacies. Coming out of the pandemic (maybe?),
For 2022, pharmacy benefits managers (PBMs) and insurers expanded their dominance over specialty dispensing, though both hospitals and physician practices are growing their share of the market. The top three PBM-owned specialtypharmacies accounted for nearly two-thirds of prescription revenues from pharmacy-dispensed specialty drugs.
Significant volume will shift to the larger players, as Centene plots its exit, Walgreens’ specialtypharmacy business collapses, and manufacturers’ 340B contract pharmacy restrictions continue. This week, I’m attending Asembia’s SpecialtyPharmacy Summit. But as I explain below, 2022 will be a year of transition.
Drug Channels Institute’s (DCI’s) latest analysis finds that participants in the specialtypharmacy market continue to get more diverse—although revenues remain highly concentrated. Read on for DCI’s latest overview of the 2023 marketplace and revenues of the biggest market participants, along with key specialtypharmacy trends.
Yesterday’s reflections on Asembia’s SpecialtyPharmacy Summit included a link to the general session slides. My portion of the deck included an updated mapping of vertical integration among insurers, PBMs, specialtypharmacies, and providers within U.S. drug channels.
Two weeks ago, Paula and I had the pleasure of attending Asembia’s 2022 SpecialtyPharmacy Summit at the wonderful Wynn Las Vegas. I offer reflections on my keynote session with Scott Gottlieb, share my experiences during the featured session, and highlight three crucial specialty industry trends.
Significant volume will shift to the larger players, as Centene plots its exit, Walgreens’ specialtypharmacy business collapses, and manufacturers’ 340B contract pharmacy restrictions continue. This week, I’m attending Asembia’s SpecialtyPharmacy Summit. But as I explain below, 2022 will be a year of transition.
The other is my mapping of the insurer/PBM/specialtypharmacy/provider organizations that now dominate U.S. One is my chart showing the key channel flows within the entire U.S. pharmaceutical distribution, payment, and reimbursement system. drug channels.
Informa Connect’s Hub and SpecialtyPharmacy Models East. June 28-30, 2022 | Sheraton Parsippany | Parsippany, NJ www.informaconnect.com/hub-specialty-pharmacy. For 2022 only, Hub and SpecialtyPharmacy Models and PAP – Patient Assistance & Access Programs are under the same roof.
It's time for Drug Channels ’ annual update of vertical integration among insurers, PBMs, specialtypharmacies, and providers within U.S. drug channels. These organizations continue to exert greater control over patient access, sites of care/dispensing, and pricing, although some have started to unwind their vertical efforts.
It's time for Drug Channels ’ annual update of vertical integration among insurers, PBMs, specialtypharmacies, and healthcare services within U.S. I’ll be joined by special guest Antonio Ciaccia, CEO of 46brooklyn Research, and President of 3 Axis Advisors. Click here to see the original post from April 2025. drug channels.
Asembia’s SpecialtyPharmacy Summit 2022. Asembia's SpecialtyPharmacy Summit 2022 is back! This is a must-attend event for anyone connected to specialtypharmacy. Plus, Doug Long from IQVIA and I will again lead the Featured Session, titled The SpecialtyPharmacy Industry Update and Outlook.
Jayne discusses changes in the life science and specialtypharmacy industries since the COVID-19 pandemic began. She highlights three key trends that pharma companies, plan sponsors, and others will consider as we head to the upcoming Asembia SpecialtyPharmacy Summit (October 26 to 29 in Las Vegas).
For 2024, DCI estimates that total prescription dispensing revenues at retail, mail, long-term care, and specialtypharmacies reached $683 billion, up 9% from the 2023 figure. It’s the 16th edition of our popular and comprehensive examination of the entire U.S. drug pricing, reimbursement, and dispensing system.
Drug Channels Institutes (DCIs) latest analysis reveals that PBM-affiliated specialtypharmacies continue to dominate the dispensing of specialty drugs. DCI has identified nearly 1,900 dispensing locations with specialtypharmacy accreditation.
Hospitals and health systems are building a major presence in the specialtypharmacy industry. As we demonstrate below, nine out of ten large hospitals now operate a specialtypharmacy. accredited specialtypharmacies. Hospitals and other healthcare providers account for one-third of all U.S.
Last week, we documented the substantial concentration of dispensing revenues for specialty drugs. See The Top 15 SpecialtyPharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents. Today, we examine how manufacturers’ specialty networks contribute to this concentration.
Last week, we documented the substantial concentration of dispensing revenues for specialty drugs. See The Top 15 SpecialtyPharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents. Today, we examine how manufacturers’ specialty networks contribute to this concentration.
In this issue: The State of SpecialtyPharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble Reconsidering Amazon P.S. Please join the nearly 13,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter. Happy Thanksgiving, everyone!
For updated data on hospital-owned specialtypharmacies, see Chapter 3 of DCI's new 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. As many of you know, hospitals and health systems have emerged as significant participants in the specialtypharmacy industry.
In this issue: The State of SpecialtyPharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon P.S. Happy Thanksgiving, everyone!
In Drug Channels Institute's list of the top 15 pharmacies of 2020 , we show that many of the largest U.S. market participants are now central-fill mail and specialtypharmacies operated by PBMs and insurers. Prime Therapeutics recently alleged that Walgreens is competing against the companies' joint venture.
specialtypharmacies. As you will note below, the specialtypharmacy industry remains quite diverse— despite the concentration of dispensing revenues within a small number of companies. It’s time for Drug Channels Institute’s annual update of the number of U.S. Fortunately, I had outstanding research assistance.
National Association of SpecialtyPharmacy (NASP) 2021 Annual Meeting & Expo. The National Association of SpecialtyPharmacy (NASP) returns to Washington, D.C. on September 27-30 for the National Association of SpecialtyPharmacy (NASP) 2021 Annual Meeting & Expo.
Below, we update our exclusive analysis of the biggest specialtypharmacies within 340B. The four largest specialtypharmacies are owned by CVS Health, Cigna’s Express Scripts business, UnitedHealth Group’s OptumRx business, and Walgreens Boots Alliance/Prime Therapeutics.
In May, I recorded a brief video webinar for an on-demand business education session at Asembia's 2020 SpecialtyPharmacy Summit Virtual Experience. You can watch the full video below.
Last week, we examined the growing concentration of specialty drug dispensing revenues among the largest pharmacies. See The Top 15 SpecialtyPharmacies of 2024: How PBMs, Health Systems, and Independents Are Shaping the Market. Today, we dive deeper. Drawing from DCIs new 2025 Economic Report on U.S.
Will COVID-19 trigger long-term share gains for specialtypharmacies as suppliers to hospitals and physician offices? Before the pandemic, specialtypharmacies—via white, brown, and clear bagging—had already displaced buy-and-bill distribution channels for a substantial chunk of provider-administered specialty drugs.
In this clip, I highlight the growth and consolidation dynamics facing the specialtypharmacy industry. I also discuss the competitive challenges facing smaller pharmacies. So below, you'll find another brief video excerpt from my May 1 Industry Update and COVID-19 Impact video webinar.
In Drug Channels Institute's list of the top 15 pharmacies of 2019 , we show that many of the largest U.S. pharmacies are now central-fill mail and specialtypharmacies operated by PBMs and insurers. I see upside for specialtypharmacies in the aftermath of the pandemic. d/b/a Drug Channels Institute.
In this issue: The State of SpecialtyPharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon Plus, the FDA preps you for Thursday with a regulatory soup review. Happy Thanksgiving, everyone!
Will COVID-19 trigger long-term share gains for specialtypharmacies as suppliers to hospitals and physician offices? Before the pandemic, specialtypharmacies—via white, brown, and clear bagging—had already displaced buy-and-bill distribution channels for a substantial chunk of provider-administered specialty drugs.
Today’s guest post comes from Megan Marchal, Director of SpecialtyPharmacy Strategy at CoverMyMeds. Megan discusses the access and affordability challenges faced by specialty therapy patients. Click here to sign up for CoverMyMeds’ Asembia SpecialtyPharmacy Summit recaps. Read on for Megan’s insights.
The battle for control of the specialty patient continues. In 2022, specialtypharmacies—via white, brown, and clear bagging—now constitute a meaningful share of the distribution channels for provider-administered oncology drugs. However, buy-and-bill appears to have rebounded substantially at hospitals.
However, Walgreens disclosed that it also generates about $16 billion in specialty revenues from its retail pharmacies and nearly 300 community-based specialtypharmacy locations. See Walgreens Launches Gene and Cell Services as Part of Newly Integrated Walgreens SpecialtyPharmacy Business.
This Valentine's Day, what could be more romantic than a deep dive into the relationships between manufacturers of specialty drugs and the pharmacies they choose for their limited and exclusive specialtypharmacy networks. As you’ll see, a typical network contains only five specialtypharmacies.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content